In the ADDitude 2023 Treatment Scorecard survey of 11,013 caregivers and adults with ADHD, only 42% of parents opt to medicate their children in the months after a diagnosis — meaning 58% delay, largely out of fear of side effects. Respondents describe regret about that delay (“I wish I had been diagnosed and treated sooner,” one wrote), but 58% measures delay prevalence, not regret prevalence: the report does not quantify what fraction of delayers regretted waiting, so 58% is an upper bound rather than a regret rate. A conservative central estimate of 40% is used here. The picture from adults diagnosed late in life reinforces the inaction direction: a 2025 Scientific Reports study of 28 women with late-diagnosed ADHD found that all participants reported negative consequences of delayed diagnosis on quality of life and mental health, and zero regretted receiving the diagnosis once it finally came. The longitudinal outcomes literature explains why: a follow-up cohort study (Journal of Abnormal Child Psychology) found young adults diagnosed with childhood ADHD were 11 times more likely to not enroll in any post-secondary education versus a four-year college compared to non-ADHD peers, and a separate population-level study found 32.3% of those with combined-type ADHD drop out of high school — more than double the 15% rate among peers without psychiatric disorders (Breslau et al., Journal of Psychiatric Research, N=29,662).
The case for caution is real and not negligible. Side effects are common: appetite suppression is the most frequent by far, affecting 61% of children taking any stimulant, followed by sleep disruption and emotional volatility. On average, families try 2.75 different medications before settling on one that works. A large population-based study (Brikell et al. 2024, Lancet Psychiatry, 1,229,972 new users across nine jurisdictions) found that 65% of children remained on ADHD medication one year after initiation — meaning roughly 35% discontinue within the first 12 months. This discontinuation rate, largely driven by side effects and perceived inadequate effectiveness, is used here as the action-side proxy for regret or ambivalence (~30%, conservatively). The landmark MTA Study (1999), which randomized 579 children ages 7–9 to medication alone, behavioral therapy alone, combined treatment, or community care, found that medication management — alone or combined — was superior to behavioral treatment alone for core ADHD symptoms at 14 months. Yet the MTA’s longer follow-up at 6–8 years showed that the initial treatment group advantages largely converged, complicating the simple “medicate early and outcomes improve” narrative.
The Relative Age Effect adds a specific caution to early diagnosis. Children born in the month before a school enrollment cutoff are approximately 34% more likely to receive an ADHD diagnosis than those born just after the cutoff (Layton et al. 2018, NEJM, n=407,846, RR≈1.34), a finding confirmed by a 2024 meta-analysis of 32 studies with a pooled relative risk of 1.38 (European Child and Adolescent Psychiatry). This suggests that developmental immaturity is being systematically misclassified as ADHD in the youngest classroom quintile, concentrating action-side regret among families whose child was younger-for-grade. The directional finding — that inaction regret substantially exceeds action regret — is consistent with Gilovich and Medvec’s temporal asymmetry framework, which predicts that roads not taken generate more lasting regret than roads taken. Both sides of this decision carry genuine cost; neither regret rate is trivial.